Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lancet Infect Dis. 2022 Dec;22(12):1716-1727. doi: 10.1016/S1473-3099(22)00502-3. Epub 2022 Sep 5.
Lancet Infect Dis. 2022.
PMID: 36075233
Free PMC article.
Clinical Trial.
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.
Wressnigg N, Hochreiter R, Zoihsl O, Fritzer A, Bézay N, Klingler A, Lingnau K, Schneider M, Lundberg U, Meinke A, Larcher-Senn J, Čorbic-Ramljak I, Eder-Lingelbach S, Dubischar K, Bender W.
Wressnigg N, et al. Among authors: corbic ramljak i.
Lancet Infect Dis. 2020 Oct;20(10):1193-1203. doi: 10.1016/S1473-3099(20)30238-3. Epub 2020 Jun 1.
Lancet Infect Dis. 2020.
PMID: 32497524
Clinical Trial.
Item in Clipboard
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
Lazarus R, Taucher C, Brown C, Čorbic Ramljak I, Danon L, Dubischar K, Duncan CJA, Eder-Lingelbach S, Faust SN, Green C, Gokani K, Hochreiter R, Wright JK, Kwon D, Middleditch A, Munro APS, Naker K, Penciu F, Price D, Querton B, Riaz T, Ross-Russell A, Sanchez-Gonzalez A, Wardle H, Warren S, Finn A; Valneva Phase 1 Trial Group.
Lazarus R, et al. Among authors: corbic ramljak i.
J Infect. 2022 Sep;85(3):306-317. doi: 10.1016/j.jinf.2022.06.009. Epub 2022 Jun 16.
J Infect. 2022.
PMID: 35718205
Free PMC article.
Clinical Trial.
Item in Clipboard
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Corbic-Ramljak I, Dubischar K, Lilja A, Eder-Lingelbach S, Hochreiter R, Jaramillo JC, Junker H, Krammer M, Pusic P, Querton B, Larcher-Senn J, Hoffmann M, Pöhlmann S, Finn A; Valneva Phase 3 Booster Trial Group.
Taucher C, et al. Among authors: corbic ramljak i.
J Infect. 2023 Sep;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022. Epub 2023 Jul 3.
J Infect. 2023.
PMID: 37406777
Clinical Trial.
Item in Clipboard
Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera.
Roques P, Fritzer A, Dereuddre-Bosquet N, Wressnigg N, Hochreiter R, Bossevot L, Pascal Q, Guehenneux F, Bitzer A, Corbic Ramljak I, Le Grand R, Lundberg U, Meinke A.
Roques P, et al. Among authors: corbic ramljak i.
JCI Insight. 2022 Jul 22;7(14):e160173. doi: 10.1172/jci.insight.160173.
JCI Insight. 2022.
PMID: 35700051
Free PMC article.
Item in Clipboard
Cellular N-myristoyltransferases play a crucial picornavirus genus-specific role in viral assembly, virion maturation, and infectivity.
Corbic Ramljak I, Stanger J, Real-Hohn A, Dreier D, Wimmer L, Redlberger-Fritz M, Fischl W, Klingel K, Mihovilovic MD, Blaas D, Kowalski H.
Corbic Ramljak I, et al.
PLoS Pathog. 2018 Aug 6;14(8):e1007203. doi: 10.1371/journal.ppat.1007203. eCollection 2018 Aug.
PLoS Pathog. 2018.
PMID: 30080883
Free PMC article.
Item in Clipboard
Cite
Cite